{"abstract":"The Food and Drug Administration (FDA, the Agency, or we) is holding a public meeting on November 7, 2019 entitled ``Promoting Effective Drug Development Programs: Opportunities and Priorities for FDA's Office of New Drugs.'' The purpose of the public meeting is to solicit specific, actionable policy suggestions that could be implemented in the near-term by the review staff of the Center for Drug Evaluation and Research's (CDER's) Office of New Drugs to promote effective drug development programs without compromising our regulatory standards for the assessment of safety and effectiveness.","action":"Notice of public meeting; request for comments.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221.json","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199.json","parent_id":221,"slug":"food-and-drug-administration"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2019/08/12/2019-17209.html","cfr_references":[],"citation":"84 FR 39856","comment_url":"http://www.regulations.gov/#!submitComment;D=FDA-2019-N-3453-0001","comments_close_on":null,"correction_of":null,"corrections":[],"dates":"The public meeting will be held on November 7, 2019, from 9 a.m. to 5 p.m. The public meeting may be extended or may end early depending on the level of public participation. Persons can attend the event in- person or via webcast. In-person attendees can also request to give a formal presentation as part of the registration process. See the SUPPLEMENTARY INFORMATION section for registration date and information. Electronic or written comments will be accepted after the public hearing until January 7, 2020.","disposition_notes":null,"docket_ids":["Docket No. FDA-2019-N-3453"],"document_number":"2019-17209","effective_on":null,"end_page":39858,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2019/08/12/2019-17209.xml","html_url":"https://www.federalregister.gov/documents/2019/08/12/2019-17209/promoting-effective-drug-development-programs-opportunities-and-priorities-for-the-food-and-drug","images":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2019-17209.json","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2019-08-12/2019-17209/mods.xml","page_length":3,"page_views":{"count":1313,"last_updated":"2019-09-15 04:15:10 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2019-08-12/pdf/2019-17209.pdf","proclamation_number":null,"public_inspection_pdf_url":"https://s3.amazonaws.com/public-inspection.federalregister.gov/2019-17209.pdf?1565354723","publication_date":"2019-08-12","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2019/08/12/2019-17209.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"document_id":"FDA-2019-N-3453-0001","agency_id":"FDA","docket_id":"FDA-2019-N-3453","regulation_id_number":null,"title":"Promoting Effective Drug Development Programs: Opportunities and Priorities for FDA\u2019s Office of New Drugs; Public Meeting","comments_count":null,"comments_url":"https://www.regulations.gov/docketBrowser?rpp=50&so=DESC&sb=postedDate&po=0&dct=PS&D=FDA-2019-N-3453","supporting_documents_count":null,"supporting_documents":[],"metadata":{}},"regulations_dot_gov_url":"http://www.regulations.gov/#!documentDetail;D=FDA-2019-N-3453-0001","significant":null,"signing_date":null,"start_page":39856,"subtype":null,"title":"Promoting Effective Drug Development Programs: Opportunities and Priorities for the Food and Drug Administration's Office of New Drugs; Public Meeting; Request for Comments","toc_doc":"Promoting Effective Drug Development Programs: Opportunities and Priorities for the Food and Drug Administration's Office of New Drugs","toc_subject":"Meetings:","topics":[],"type":"Notice","volume":84}